Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 303-307

  Pajkrt, Dasja ^a   Lerch, Peter G ^b   Van Der Poll, Tom ^a   Levi, Marcel ^c   Illi, Marlies ^b   Doran, Jan E ^b   Arnet, Beat ^b   Van Den Ende, Abraham ^c   Ten Cate, Jan Wouter ^c   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Central Laboratory in Bern   (Switzerland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

EID: 0031045302     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655958     Document Type: Article

References (41)

1. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leucocytes in patients with sepsis and multiple organ failure. Eur J Clin Invest 1995; 25: 843-51.
2. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-9.
3. ten Cate H, Brandjes DPM, Wolters HJ, van Deventer SJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horizons 1993; 1: 312-23.
4. Emancipator K, Csako G, Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60: 596-601.
5. Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
6. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 252-6.
7. Csako G, Suba EA, Elin RJ. Endotoxin-induced platelet activation in human whole blood in vitro. Thromb Haemost 1998; 59: 378-82.
8. 2 production by human platelets. Am J Hematol 1981; 11: 159-64.
9. Gralnick HR , Elin R, Abrans E, Givelber H, Wolff SM. Effects of endotoxin (LPS) on blood coagulation in humans. Clin Res 1976; 24: 344A.
10. Cohen P, Braunwald J, Gradner FH. Destruction of canine platelets and rabbit platelets following intravenous administration of carbon particles or endotoxin. J Clin Lab Med 1965; 66: 263-71.
11. 2) on endotoxic shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 1980; 7: 299-308.
12. Spielvogel AR. An ultrastructural study of the mechanisms of platelet-endotoxin interaction. J Exp Med 1967; 126: 235-50.
13. Flegel WA, Wölpl A, Männel DA, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-45.
14. Baumberger C, Ulevitch RJ, Dayer JM. Modulation of endotoxin activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 1991; 59: 378-83.
15. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low-and high-density lipoproteins and by apolipoprotein A-1. Infect Immun 1993; 61: 5140-6.
16. Levine DM, Parker TS, Donelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-4.
17. Parker TS, Levine DM, Chuang JCC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lippolysaccharides in human whole blood. Infect Immun 1995; 63: 253-8.
18. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-1 containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circulatory Shock 1993; 40: 14-23.
19. Cué JI, Di Piro JT, Brunner LJ, Doran JE, Blankenship ME, Mansberger AR, Hawkins ML. Reconstituted high-density lipoprotein inhibits physiologic and tumor necrosis factor α responses to lipopolysaccharide in rabbits. Arch Surg 1994; 129: 193-7.
20. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role of circulating lipoproteins in protection from endotoxin activity. Infect Immun 1995; 63: 2041-6.
21. Malyszko J, Urano T, Knofler R, Ihara H, Takada Y, Takada A. Relationships between serum lipids, serotonin, platelet aggregation and some fibrinolysis parameters in humans. Life Science 1994; 55: 1619-23.
22. Koller E, Koller F, Doleschel W. Specific binding sites on human platelets for plasma lipoproteins. Hoppe-Seyler's Z Physiol Chem 1982; 363: 395-405.
23. Koller E, Koller F, Binder BR. Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989; 264: 12412-8.
24. Malle E, Sattler W. Platelets and lipoproteins: native, modified and platelet modified lipoproteins. Platelets 1994; 5: 70-83.
25. Surya II, Akkerman JWN.The influence of lipoproteins on blood platelets. Am Heart J 1993; 125: 272-5.
26. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJH. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 180: 1601-8.
27. Lerch PG, Förtsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein (rHDL) for therapeutic applications. Vox Sang 1996; 71: 155-164.
28. 23). J Infect Dis 1995; 172: 144-51.
29. Van der Poll T, Levi M, Hack CE, van Deventer SJH, ten Cate H, Haagmans B, Biemond BJ, H, Büller HR, ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-51.
30. Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJH. Eerenberg AJM, de Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of Interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9.
31. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apoliporoteins of high denity lipoproteins in man. Thromb Res 1985; 39: 1-8.
32. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM. HDL and Apolipoprotein A-1 protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994; 14: 1775-83.
33. Waysbort J, Schwartz S, Brunner D. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients. Arzneim Forsch 1994; 44: 1217-22.
34. Sermet A, Aybak M, Ulak G, Güzel C, Denli O. Effect of oral pyridoxine hydrochloride supplementation on in vitro platelet sensitivity to different agents. Arzneim Forsch 1995; 45: 19-21.
35. Higashihara M, Kinoshita M, Teramoto T, Kume S, Kurokawa K. The role of ApoE in inhibitory effects of apoE-rich HDL on platelet function. FEBS 1991; 282: 82-6.
36. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-1 (apoA-1). J Clin Invest 1988; 82: 803-7.
37. Radomski MW, Palmer RMJ, Moncada S. Characterization of the L-arginine: nitic oxide pathway in human platelets. Br J Heamatol 1990; 101: 325-8.
38. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Science 1994; 55: 1815-21.
39. Satoh K , Imaizumi TA, Yoshida H, Takamatsu S. High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells. J Clin Lab Med 1994; 124: 225-31.
40. Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 1996; 13: 73-88.
41. Surya II, Gorter G, Akkerman JW. Arachidonate transfer between platelets and lipoproteins. Thromb Haemost 1992; 68: 719-26.